Background and objective: A structural single nucleotide polymorphism rs721917 in the surfactant protein D (SP-D) gene, known as Met11Thr, was reported to influence the circulating levels and degree of multimerization of SP-D and was associated with both COPD and atopy in asthma. Moreover, disease-related processes are known to degrade multimerized SP-D, however, the degree of the protein degradation in these diseases is not clarified. We aimed to determine the distribution of multimerized (high molecular weight (HMW)) and nonmultimerized (low molecular weight (LMW)) species of serum SP-D and their correlation with genetic polymorphisms and presence of disease in Lebanese COPD and asthmatic patients. Methods: Serum SP-D levels were measured by ELISA in 88 COPD, 121 asthmatic patients and 223 controls. Randomly selected subjects were chosen for genotyping of rs721917 and multimerization studies. HMW and LMW SP-D were separated by gel permeation chromatography. Results: Serum SP-D levels were significantly increased in patients with COPD, but not in asthmatic patients, when compared to controls. Met11Thr variation strongly affected serum SP-D levels and the degree of multimerization, but was not associated with COPD and asthma in the study. Remarkably, HMW/LMW serum SP-D ratio was significantly lower in Met11/Met11 COPD and asthmatic patients compared to controls. Conclusion: Collectively, non-multimerized species of serum SP-D were dominant in COPD and asthmatic patients suggesting that degradation of SP-D takes place to a significant degree in pulmonary disease. Assays that can separate SP-D proteolytic breakdown products or modified forms from naturally occurring SP-D trimers may result in optimal disease markers for pulmonary inflammatory diseases.
INTRODUCTION
COPD and asthma represent major health burdens worldwide. COPD leads to significant morbidity and mortality and is predicted to be the third leading cause of death by 2020, while asthma is becoming increasingly frequent in recent decades. 1, 2 Despite guidelines and efficient treatments, COPD and asthma have unmet medical needs due to late diagnosis of COPD and unresponsiveness of some asthma patients to high dosages of corticosteroids. 3, 4 The availability of good surrogate markers that can track disease progression and predict clinical outcomes will aid in the development and testing of novel treating compounds for both diseases. A considerable number of potential biomarkers have been suggested to date, however, they need further validation to be routinely used in clinical practice.
SUMMARY AT A GLANCE
We demonstrated for the first time in a Lebanese population cohort that non-multimerized species of serum surfactant protein D (SP-D) were dominant in Met11/Met11 COPD and asthmatic patients suggesting that degradation of SP-D takes place to a significant degree in pulmonary diseases.
systemic biomarker for prognosis of various pulmonary diseases. 8, 9 In COPD, serum SP-D was found to be associated with the BODE index of severity 10 and to mortality. 11 However, serum SP-D levels were not found to be associated with COPD disease severity in the ECLIPSE study 12 as well as in other additional smaller studies. [13] [14] [15] Surfactant protein D (SP-D) is a member of the collectin family with pivotal roles in innate immunity. It is a pattern recognition receptor that binds to a variety of respiratory pathogens, enhancing their clearance. 16 It is also involved in the modulation of allergic responses and pulmonary inflammation. 8, 17 Human SP-D is mainly secreted as a dodecameric cruciform formed by the assembly of four homotrimeric subunits, which can be further assembled into higher-order fuzzy ball-like multimers that can contain 32 (or more) trimeric subunits. 18, 19 Oligomerization state of SP-D is an important determinant of its function. Anti-microbial and antiinflammatory properties have been attributed to multimeric SP-D variants, while trimeric subunits have been suggested to enhance inflammation. 17, 20 SP-D is easily detectable in serum and measured levels remain stable over a 6-month period. 21 Previous studies have shown that multimerized (high molecular weight (HMW)) and non-multimerized (low molecular weight (LMW)) SP-D are interconvertible structures. 22 The HMW/LMW ratio is dependent on several factors such as posttranslational modifications of SP-D by glycosylation and, in surrounding inflammatory conditions, by nitrosylation, oxidative damage and proteolytic degradation which result in degradation of SP-D multimers and release of LMW breakdown products. 6, [23] [24] [25] Several pieces of evidence showed that constitutional SP-D serum levels and the protein degree of multimerization are genetically determined. 22, 26 A single nucleotide polymorphism (SNP) rs721917 in the coding region of the SP-D gene (SFTPD), known as Met11Thr, that results in an amino acid change from methionine to threonine at position 11 of the mature protein, was shown to have a strong effect. 26 Besides alterations in serum SP-D levels and multimerization, genetic variations in SFTPD gene have been also associated with several pulmonary inflammatory diseases including COPD and asthma. 12, [27] [28] [29] However, the specific SNP-associations have not been validated in all investigated populations 30 suggesting distinct genetic influences on COPD susceptibility and SP-D levels. On the other hand, structural SP-D polymorphisms were not found in association with allergic bronchial asthma 31 whereas an association was found with decreased atopy in black subjects. 32 Thus, these data are not conclusive and the exact correlation is not yet clear.
Previous studies on COPD and asthma patients documented decreased SP-D levels in bronchoalveolar lavage (BAL) concomitant with increased levels in serum and suggested that this might be due to increased air-blood barrier permeability in the lung facilitating the leakage of LMW SP-D/breakdown products into the serum. 6, 12, 33 One single recent paper 33 reported the presence of degraded fragments of SP-D in serum of severe asthmatic patients. However, to date, the distribution of multimerized and nonmultimerized SP-D forms in pulmonary inflammatory diseases and its association with genetic variations remain unknown. In the present study, correlations between SFTPD gene SNP rs721917, COPD and asthma, serum SP-D levels and SP-D multimerization were evaluated. We aimed to investigate which genetic variation determines SP-D multimerization in COPD and asthma and if the degree of serum SP-D multimerization was significantly changed by the presence of respiratory disease.
METHODS

Study design and subjects
During the period from June 2011 to April 2013, 90 COPD and 123 asthmatic patients were recruited from the outpatient clinics of the Pulmonology Department of the Saint George Hospital University Medical Center, Beirut, Lebanon. In addition, a total of 223 controls were recruited from the general population. 15 All participants were 18 years old or above. Healthy subjects were non-smokers and had no previous or current diagnosis of any chronic respiratory disease such as asthma, COPD, chronic bronchitis, fibrosis, tuberculosis or lung cancer. Furthermore, these subjects were not suffering from any respiratory symptoms or nonrespiratory diseases such as diabetes or cardiovascular disease. COPD diagnosis was defined according to the Global Initiative for Chronic Obstructive Lung disease (GOLD) criteria. 34 Ninety COPD patients were classified into categories based on GOLD 2013. None of the patients had an exacerbation within 1 month prior to the inclusion. Asthmatic patients (n = 124) were diagnosed according to GINA guidelines 2012 (Global initiative for asthma). 35 Having another respiratory disease was the exclusion criterion for COPD or asthma patients. The study was approved by the Ethical Committee of the Faculty of Pharmacy at the Lebanese University. All participants signed a written informed consent and filled out a detailed questionnaire, based on the American Thoracic Society Questionnaire. 36 
Pulmonary function test and blood collection
Patients were subjected to baseline spirometry measurements by a trained physician. 15 Peripheral blood samples were collected by venipuncture from all study participants into ethylenediaminetetraacetic acid (EDTA) vacutainer or dry tubes for leukocytes and serum collection, respectively. These samples were centrifuged at 3000 rpm at 4 C within 12 h after withdrawal. Serum was aliquoted and stored at −20 C. Leukocyte DNA was isolated and stored at −80 C.
Measurement of serum SP-D
SP-D was quantified in serum by ELISA as described earlier by Leth-Larsen et al. 37 Details of the method are provided in Appendix S1 in Supplementary Information. Calibrators, controls and samples were tested in duplicate and the coefficient of variation average was 4.83%.
SNP genotyping
Genomic DNA was extracted from 115 healthy subjects, 62 COPD and 97 asthmatic patients using a standard salting-out method. 38 Following DNA quantification, exon 2 of the SFTPD gene was amplified and sequenced, as detailed in Appendix S2 in Supplementary Information. The genotype distribution was conformed with Hardy-Weinberg Equilibrium (HWE) in the healthy participants, COPD patients and asthmatic patients.
Gel permeation chromatography
Human serum samples (0.2 mL) from randomly selected genotyped healthy individuals (n = 57), COPD (n = 36) and asthmatic (n = 53) patients were separated by gel permeation chromatography (GPC), as described earlier by Sorensen et al. 22 Samples were applied to an analytical Superose 6 10/300 GL column (17-5172-01, GE Healthcare, Uppsala, Sweden) connected to an FPLC (fast protein liquid chromatography) system using TBS (Tris-buffered saline), pH 7.4, 10 mM EDTA and 0.05% Emulphogen as eluent at a flow rate of 24 mL/h. Fractions of 0.2 mL were collected using 96-well plates and further quantified by the SP-D ELISA. 37 Details of the GPC procedure and analyses are given in Appendix S3 in Supplementary Information.
Statistical analysis
Serum SP-D levels and HMW/LMW ratio were not normally distributed even after log transformation and were expressed as inter-quartile range. Differences between groups were tested using the t-test for the association between age and the disease, the chisquare test for the associations between sex, BMI, smoking and the disease or SNPs and the disease, and one-way analysis of variance (ANOVA) for the association between SP-D levels and the disease. Variation of HMW/LMW serum SP-D ratio with genotype and diseases was tested by one-way ANOVA followed by Bonferroni test. Non-parametric tests yielded the same results. Logistic regressions were used to test the associations between COPD or asthma and HMW/LMW serum SP-D ratio after adjustment for rs721917 and the potential confounding variables such as age, BMI, sex and smoking.
Based on previously reported results on SP-D in COPD, a minimum of 32 patients and 46 controls was required for the study based on a power of 80% and an alpha error of 5%. 39 
RESULTS
Characteristics of COPD patients, asthma patients and healthy participants are presented in Table 1 . The three groups were significantly different regarding age, gender and smoking status as previously reported. 15 COPD patients had significantly higher serum SP-D levels compared with healthy controls (P < 0.001) and asthma patients (P = 0.02). Median serum SP-D level was 1510 ng/mL (986-2174) in COPD patients, 1122 ng/mL (569-1624) in controls and 1130 ng/mL (676-1852) in asthma patients.
rs721917 polymorphism within SFTPD gene and serum SP-D levels in COPD and asthma
The distribution of genotypes and alleles frequencies of the rs721917 SNP and corresponding serum SP-D levels in controls and patients are shown in Table 2 .
The rs721917 SNP genotype distribution did not differ significantly between healthy controls and COPD patients (P = 0.8) or asthma patients (P = 0.3). The rs721917 polymorphism was significantly correlated with constitutional serum SP-D levels in healthy Lebanese participants (P < 0.001). Met11/Met11-genotyped individuals had the highest serum SP-D levels whereas Thr11/Thr11-genotyped individuals had the lowest. A similar effect of the SNP variation on the serum SP-D level was observed when COPD patients (P = 0.005) and asthma patients (P = 0.005) were stratified according to their Met11Thr genotype.
rs721917 variation and serum SP-D multimerization in COPD and asthma GPC data showed that serum from healthy Met11/ Thr11-genotyped individuals revealed two almost equivalent peaks of serum SP-D HMW and LMW species (Fig. 1B) . In contrast, serum from Met11/Met11-and Thr11/Thr11-genotyped individuals showed a predominance of the HMW SP-D and the LMW SP-D forms, respectively (Fig. 1A-C) .
Based on the rs721917 genotype, the HMW/LMW serum SP-D ratio in healthy participants showed high variability and presented an interquartile range of (0.34-3.26; n = 56). The ratio was highest in the sera of Met11/Met11-genotyped individuals (3.01-5.19; n = 21), lower in Met11/Thr11-genotyped individuals (1.07-2.06; n = 18) and lowest in Thr11/Thr11-genotyped individuals (0.02-0.34; n = 18) (Fig. 1D) . All values are expressed as n (%) except for age expressed as Median (Q1;Q3). Q, quartile.
These differences were statistically significant (P < 0.0001). Similar significant distribution patterns were observed within the COPD (P < 0.0001) and asthma patient groups (P < 0.0001). The HMW/LMW serum SP-D ratio was significantly altered in COPD and asthma when compared to healthy individuals. The ratio significantly decreased in COPD (P = 0.014) and asthmatic patients (P = 0.027) compared to controls (Fig. 2) . Our results further show that decreased HMW/LMW ratio was highly significant in the Met11/Met11 individuals for both COPD and asthmatic patients (P < 0.0001) (Fig. 3) . However, multivariate logistic analysis, including age, BMI, gender, smoking status and rs721971 genotypes as covariates, revealed that the HMW/LMW serum SP-D ratio was independently associated with COPD (P = 0.005) and asthma (P < 0.0001) ( Table 3) .
DISCUSSION
The present study investigated the association of the rs721917 genotype with serum SP-D levels in COPD and asthma patients, and examined for the first time the influence of rs721917 variation on SP-D size variation in these two respiratory diseases. As we reported earlier, serum SP-D levels were significantly increased in COPD patients as compared to healthy controls and asthma patients. 15 Previous studies reported an increased level in serum concomitant with decreased SP-D level in BAL that is most probably due to an increased alveolar-capillary permeability, increased lung production and/or decreased clearance of SP-D from the circulation in inflammatory states. 6, 12 Furthermore, a recent study reported that alveolar epithelial injury after LPS inhalation in humans was more severe in smokers than non-smokers, with increased plasma and decreased BAL SP-D. 40 Several studies have linked rs721917 with clinical pathologies, which may suggest involvement of SP-D size variation in pathogenesis. Association of polymorphisms or haplotypes of SFTPD with COPD, emphysema and COPD survival has been observed in various populations and by genome-wide association studies (GWAS). 28, 29, 41, 42 However, in the present study, the Met11Thr genotype distribution amongst Lebanese COPD and asthma patients did not significantly differ from the healthy population. Our data are in accordance with previous studies that did not support an rs721917 association to COPD 43 or to asthma. 31 The obtained results showed that the polymorphism rs721917 within SFTPD gene strongly affected constitutional serum SP-D levels and the degree of protein multimerization which is in accordance with previous observations.
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Met11/Met11-genotyped individuals had the highest serum SP-D levels and the predominance of the HMW SP-D form whereas Thr11/Thr11-genotyped individuals had the lowest serum levels and lacked the HMW SP-D forms. Our SP-D multimerization data, with a sufficiently large sample size confirm previous findings in a healthy Danish population. 26 The molecular size distribution between the high and low forms of SP-D, separated by size-permeation chromatography was previously shown by Western blotting and confirmed by atomic force microscopy which demonstrated that the SP-D LMW form isolated from amniotic fluid consisted predominately of trimeric subunits, whereas a mixture of trimeric, dodecameric and multimeric forms was present in the SP-D HMW form. 22, 26 In the study reported here, we demonstrated that a relatively higher proportion of LMW SP-D was Figure 2 Variation of HMW/LMW serum SP-D ratio with inflammatory diseases COPD and asthma. SP-D structural forms in serum were separated using gel permeation chromatography followed by SP-D quantification in every fraction by ELISA. Integration of the area under the curves was performed to detect average distribution of (HMW) SP-D to (LMW) SP-D for COPD (n = 36), asthmatics (n = 53) and controls (n = 57). The horizontal bars represent the mean values. One-way ANOVA followed by Bonferroni test was used to detect the significant differences between controls and patients. *P-value < 0.05. ANOVA, analysis of variance; HMW, high molecular weight; LMW, low molecular weight; ns, non-significant; SP-D, surfactant protein D. significantly associated with COPD and asthma and partly dependent on Met11Thr genotypes. To our knowledge, this is the first quantitative study of SP-D multimerization in COPD and asthma patients.
Previous qualitative studies have shown that acute allergic inflammation and cigarette smoking induce disruption of SP-D multimers in BAL. 6, 44 Kotecha and colleagues investigated the multimeric heterogeneity of SP-D in BAL of cystic fibrosis patients and reported a remarkable functional diversity since only high multimeric forms showed a lectin activity. 45 In another recent study, MacKay and colleagues reported an increase in serum SP-D and detected the presence of degraded LMW fragments of SP-D in the serum of severe asthmatic patients. 33 These findings correlate well with our observations regarding an increase in serum SP-D concentration and an abundance of LMW SP-D species in the serum of these patients.
The degradation of SP-D multimers could be due to post-translational modifications by reactive oxygen and nitrogen species (ROS and RNS). These species, derived from cigarette smoke or released by immune cells during inflammation, play a role in the pathogenesis of inflammatory respiratory disorders. In addition, this increase in serum LMW forms of SP-D in COPD and asthma patients might be due to formation of S-nitrosothiol (SNO)-SP-D and/or increased proteolytic degradation during the chronic inflammatory lung conditions.
There are some limitations to our study. First, the detector antibody used in the ELISA assay is raised against the neck carbohydrate recognition domain (CRD) and therefore is expected to recognize all SP-D forms including those modified at the N-terminus (SNO-SP-D, fucosylated) and degraded at the Nterminus or collagen domains. Second, the GPC only allowed significant detection of HMW and LMW differences in Met/Met subjects and not in Thr/Thr subjects since the size separation technique does not separate natural trimers from breakdown products or modified SP-D unable to form multimers. To date, attempts to monitor LMW SP-D or breakdown products of SP-D are few and mostly based on the use of native gelelectrophoresis, which may not be applicable to largescale analysis. The development of immunoassay-based methods, which have been used previously to detect circulating extracellular matrix epitopes 46, 47 are needed for studies of SP-D breakdown product variation in respiratory diseases.
In conclusion, the degradation of serum SP-D from HMW into LMW forms was detected in the investigated respiratory diseases, and mainly evident in Met11/ Met11 COPD and asthmatic patients. New means to monitor breakdown products or modified LMW forms of serum SP-D as a pulmonary disease marker are warranted. 
